A Reliability Tier Classification System (RTCS) for Marketed Exosome-Based Products to Facilitate Clinical...

Area of Science:

• Extracellular Vesicles Research
• Dermatology and Aesthetic Medicine
• Biotechnology and Product Development

Background:

• Exosomes, crucial for intercellular communication, are utilized in various commercial products.
• Significant variability exists in the composition, regulation, and scientific backing of marketed exosome-based products.
• This variability poses challenges for clinicians seeking reliable and evidence-based options in dermatology and aesthetic practices.

Purpose of the Study:

• To introduce the Reliability Tier Classification System (RTCS) as a tool for clinical decision-making.
• To provide a structured framework for categorizing exosome-based products and related devices.
• To enhance the selection of safe and scientifically supported exosome therapies.

Main Methods:

• The RTCS employs a two-component system: Descriptive Product Classification and Hierarchical Categorization Algorithm.
• Product classification assesses regulatory status, origin, manufacturing transparency, and scientific evidence.
• The algorithm assigns products to one of four reliability tiers (I-IV) based on these assessments.

Main Results:

• RTCS standardizes nomenclature for regulatory status (DRUG, MD, COS, NA) and origin (AUTO, ALLO, XENO, MIM).
• Manufacturing reliability is assessed via a composite transparency score, including labeling accuracy, certification, and evidence availability.
• The system provides a clear output for evaluating exosome product reliability.

Conclusions:

• The RTCS offers a structured approach for clinicians to evaluate marketed exosome-based products.
• This tool addresses the challenges posed by a rapidly expanding and variably documented marketplace.
• The RTCS is designed to be adaptable to evolving regulatory policies and scientific evidence, serving as a foundation for future validation.